:max_bytes(150000):strip_icc()/health-GettyImages-2025836701-ce3f5ccf0f98428e9d14abaeb07ba307.jpg)
Pay in 4 interest-free payments of $5.68 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Around 82 percent see no change in their buying
Recent approvals include EGFR monoclonal antibodies (e.g., Necitumumab) [5] and immune checkpoint inhibitors (e.g., Pembrolizumab, Tislelizumab, Sintilimab) [6,7,8], while platinum-immunotherapy combinations have now become the standard first-line treatment for metastatic disease [9, 10]
A collaborative study
2025:ehaf602
Supplementary information Rights and permissions Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s)
US$ 27.66
US$ 22.82
US$ 29.69
US$ 27.77
US$ 24.12
US$ 29.42
US$ 27.29
US$ 22.66
US$ 26.07
US$ 23.75
